Peter Greenleaf Sells 797 Shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS) Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Peter Greenleaf sold 797 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $26.13, for a total transaction of $20,825.61. Following the transaction, the director owned 23,884 shares in the company, valued at $624,088.92. The trade was a 3.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Trading Up 13.8%

NYSEAMERICAN:PTHS opened at $28.00 on Thursday. Pelthos Therapeutics Inc. has a 12 month low of $16.09 and a 12 month high of $37.50. The company has a debt-to-equity ratio of 1.41, a current ratio of 2.79 and a quick ratio of 1.86. The firm has a market capitalization of $97.44 million, a PE ratio of -1.36 and a beta of 3.10. The business has a fifty day moving average of $26.83.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its quarterly earnings data on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The firm had revenue of $10.91 million for the quarter. Equities analysts predict that Pelthos Therapeutics Inc. will post -12.63 earnings per share for the current fiscal year.

Institutional Trading of Pelthos Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in PTHS. Knott David M Jr boosted its holdings in Pelthos Therapeutics by 9.3% during the first quarter. Knott David M Jr now owns 21,073 shares of the company’s stock worth $443,000 after purchasing an additional 1,792 shares during the last quarter. Geode Capital Management LLC increased its stake in Pelthos Therapeutics by 31.9% in the 4th quarter. Geode Capital Management LLC now owns 13,625 shares of the company’s stock valued at $422,000 after buying an additional 3,295 shares during the last quarter. Persistent Asset Partners Ltd increased its stake in Pelthos Therapeutics by 150.0% in the 4th quarter. Persistent Asset Partners Ltd now owns 6,007 shares of the company’s stock valued at $186,000 after buying an additional 3,604 shares during the last quarter. Pale Fire Capital SE lifted its position in shares of Pelthos Therapeutics by 59.5% during the 1st quarter. Pale Fire Capital SE now owns 12,919 shares of the company’s stock worth $271,000 after buying an additional 4,819 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of Pelthos Therapeutics during the 4th quarter worth approximately $343,000. Hedge funds and other institutional investors own 77.96% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Oppenheimer increased their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a report on Friday, May 15th. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 24th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Pelthos Therapeutics in a research note on Thursday, March 19th. Finally, Cantor Fitzgerald started coverage on shares of Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 target price for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.80.

About Pelthos Therapeutics

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).